· ST-SAF-04 · v2
The claim is that roughly 5 to 10 out of every 100 people taking statins get muscle symptoms in everyday care. Only one study in this corpus actually measured that in a real-world setting: a large Italian clinic cohort of 16,717 patients, where 9.6% reported muscle symptoms [6] — just inside the top edge of the claimed band. Other evidence pulls in different directions: a trial of new statin users found 31% reporting symptoms [1], while another paper cites a background figure of 10% to 25% [3]. The same real-world study also found that when patients stopped and restarted the drug, only about 3% reproduced their symptoms [6], which is below the claimed floor. So the specific 5 to 10 band rests on a single study sitting at its ceiling, with the surrounding evidence spread both higher and lower.
The only direct real-world prevalence estimate in the corpus is the PROSISA cohort, which found reported muscle symptoms in 9.6% of 16,717 statin-treated patients in routine lipid-clinic practice [6], landing at the top of the 5-10% band. A trial of new statin users reported a much higher 31% on both active and placebo arms [1], and a separate paper cites a background rate of 10% to 25% [3]. Within the same PROSISA cohort, symptoms reappeared after dechallenge/rechallenge in only 3.01% of the whole cohort [6]. The corpus therefore contains exactly one primary estimate aligned with the claim, surrounded by figures that run both above and below it. The contested point: The division is whether a single real-world estimate at 9.6% [6] can establish a 5-10% range when the one trial-based reported rate in the corpus is 31% [1] and the attributable rate after rechallenge in that same cohort is only 3.01% [6]. The panel agreed the figure is supported but not firmly established, because reported-symptom rates vary sharply by setting and the band sits on one study at its ceiling.
All 18 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Statins, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The 5-10% band is carried by a single primary prevalence study ([6], 9.6%) sitting at the very top edge; one estimate cannot establish a range in clinical practice.
In [6], after dechallenge/rechallenge only 3.01% of the whole cohort reproduced symptoms, so true statin-attributable prevalence may fall below the claimed 5% floor.
Where it remains uncertain. A new-user trial reported 31% [1] and a cited background range was 10% to 25% [3], while dechallenge/rechallenge in PROSISA reproduced symptoms in only 3.01% [6].
Aleatory
Reported-symptom rates vary widely by population and setting, from 9.6% in a real-world cohort [6] to 31% in a new-user trial [1].
Epistemic
Only one corpus study directly measures real-world prevalence [6], so the band rests on one data point with no independent replication.
The load-bearing papers from a corpus of 18, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Counter-evidence: reported SAMS reach 31% in new statin users and are identical on placebo (nocebo), well above 5-10%.
“SAMS were reported by 317 participants (31%) assigned vitamin D and 325 assigned placebo (31%)”
Panel auditInternal validity: medium · scope of inference: Cancer- and CVD-free adults aged ~67 who initiated statins during a vitamin D trial.Key limitations: self-reported SAMS · no excess over placebo · trial cohort not general practice · retrospective survey
Directly supports the claim: 9.6% reported SAMS in a real-life clinical cohort, at the top of the 5-10% band.
“with reappearance of muscular symptoms in 38.4% (3.01% of the whole cohort)”
Panel auditInternal validity: medium · scope of inference: Dyslipidaemic patients treated at Italian lipid clinics in routine practice.Key limitations: self-reported SAMS · retrospective · confirmed rate much lower after rechallenge
Cites a higher 10-25% range, showing the prevalence estimate is contested and not settled at 5-10%.
“Evidence suggests 10% to 25% of patients experience statin-associated muscle symptoms (SAMS)”
Panel auditInternal validity: not assessable from abstract · scope of inference: General statin-treated patients, per cited literature.Key limitations: secondary citation · no primary denominator · abstract fragment only
3 of 18 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A single primary real-world study lands the claim at the top of its range while other corpus evidence spreads both above and below it, so the corpus supports but does not firmly establish 5-10%.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Independent real-world prevalence replication. The 5-10% band rests on one cohort [6] at its ceiling; a second, independent real-world estimate is needed to confirm the range. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A large multi-country observational cohort measuring reported SAMS prevalence in unselected statin-treated patients in routine care.
Open question: What is the statin-attributable prevalence of muscle symptoms in routine clinical practice, as opposed to the reported rate? Why it is still open: In [6] 9.6% reported SAMS but only 3.01% reproduced symptoms on dechallenge/rechallenge, and [1] shows identical rates on statin and placebo.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 26 Oct 2026 · protocol v0.19